5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.

about

5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.

Item

http://www.wikidata.org/entity/Q52653016

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

5-FU therapeutic drug monitori ...... with gastrointestinal cancer.

@en

5-FU therapeutic drug monitori ...... with gastrointestinal cancer.

@nl

type

Item

label

5-FU therapeutic drug monitori ...... with gastrointestinal cancer.

@en

5-FU therapeutic drug monitori ...... with gastrointestinal cancer.

@nl

prefLabel

5-FU therapeutic drug monitori ...... with gastrointestinal cancer.

@en

5-FU therapeutic drug monitori ...... with gastrointestinal cancer.

@nl

P1476

5-FU therapeutic drug monitori ...... with gastrointestinal cancer.

@en

P2093

Adèle Cueff

http://www.w3.org/2001/XMLSchema#string

Antonin Schmitt

http://www.w3.org/2001/XMLSchema#string

Aurélie Bertaut

http://www.w3.org/2001/XMLSchema#string

François Ghiringhelli

http://www.w3.org/2001/XMLSchema#string

Françoise Goirand

http://www.w3.org/2001/XMLSchema#string

Julie Vincent

http://www.w3.org/2001/XMLSchema#string

Katarzyna Morawska

http://www.w3.org/2001/XMLSchema#string

Laurine Marceau

http://www.w3.org/2001/XMLSchema#string

Leila Bengrine-Lefevre

http://www.w3.org/2001/XMLSchema#string

Madeline Devaux

http://www.w3.org/2001/XMLSchema#string

P2860

Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.

A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.

Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.

P304

11559-11571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24338

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

François Ghiringhelli

P577

2018-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29545919

http://www.w3.org/2001/XMLSchema#string

P932

5837758

http://www.w3.org/2001/XMLSchema#string